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RESEARCH ARTICLE
Targeting tubulointerstitial remodeling in proteinuric nephropathy
in rats
Saleh Yazdani1,*,‡, Ryanne S. Hijmans1,*, Fariba Poosti2, Wendy Dam1, Gerjan Navis1, Harry van Goor2 and
Jacob van den Born1
ABSTRACT
Proteinuria is an important cause of tubulointerstitial damage. Anti-
proteinuric interventions are not always successful, and residual
proteinuria often leads to renal failure. This indicates the need for
additional treatment modalities by targeting the harmful downstream
consequences of proteinuria. We previously showed that proteinuria
triggers renal lymphangiogenesis before the onset of interstitial
inflammation and fibrosis. However, the interrelationship of these
interstitial events in proteinuria is not yet clear. To this end, we
specifically blocked lymphangiogenesis (anti-VEGFR3 antibody),
monocyte/macrophage influx (clodronate liposomes) or lymphocyte
andmyofibroblast influx (S1Pagonist FTY720) separately in a rat model
to investigate the role and the possible interaction of each of these
phenomena in tubulointerstitial remodeling in proteinuric nephropathy.
Proteinuria was induced in 3-month old male Wistar rats by adriamycin
injection. After 6 weeks, when proteinuria has developed, rats
were treated for another 6 weeks by anti-VEGFR3 antibody,
clodronate liposomes or FTY720 up to week 12. In proteinuric rats,
lymphangiogenesis, influx of macrophages, T cells and myofibroblasts,
and collagen III deposition and interstitial fibrosis significantly
increased at week 12 vs week 6. Anti-VEGFR3 antibody prevented
lymphangiogenesis in proteinuric rats, however, without significant
effects on inflammatory and fibrotic markers or proteinuria. Clodronate
liposomes inhibitedmacrophage influx and partly reducedmyofibroblast
expression; however, neither significantly prevented the development of
lymphangiogenesis, nor fibrotic markers and proteinuria. FTY720
prevented myofibroblast accumulation, T-cell influx and interstitial
fibrosis, and partially reduced macrophage number and proteinuria;
however, it did not significantly influence lymphangiogenesis and
collagen III deposition. This study showed that proteinuria-induced
interstitial fibrosis cannot be halted by blocking lymphangiogenesis or
the influx of macrophages. On the other hand, FTY720 treatment did
prevent T-cell influx, myofibroblast accumulation and interstitial fibrosis,
but not renal lymphangiogenesis and proteinuria. We conclude that
tubulointerstitial fibrosis and inflammation are separate from
lymphangiogenesis, at least under proteinuric conditions.
KEY WORDS: Proteinuria, Renal lymphatic, Lymphangiogenesis,
Renal fibrosis, Renal inflammation
INTRODUCTION
Proteinuria is a major challenge in clinical nephrology because
sustained proteinuria can lead to a progressive decline in
kidney function, worsening to chronic kidney disease (CKD)
and end-stage renal disease (ESRD), and eventually the need
for dialysis or renal transplantation (Cravedi and Remuzzi,
2013; Ruggenenti et al., 2012; Lea et al., 2005; Gorriz and
Martinez-Castelao, 2012). Many renal diseases are accompanied
by proteinuria. Because proteinuria is independently associated
with a decline in renal function, anti-proteinuric treatment [mainly
renin-angiotensin-aldosterone system (RAAS) intervention,
eventually in combination with reduced salt intake] makes up a
major cornerstone in renal medicine. Nevertheless, complete
annihilation of proteinuria is practically not possible, and most
patients slowly progress towards renal failure. Forced titration of
proteinuria by dual RAAS intervention (ONTARGET trial) or
angiotensin-converting enzyme (ACE) inhibition under very-low-
salt conditions worsened renal outcomes (Mann et al., 2008) or
interstitial fibrosis (Hamming et al., 2006). Even under rather low
proteinuria values kidneys deteriorate over time. This indicates the
need for additional treatment modalities, not only trying to reduce
proteinuria even further, but also reduce the harmful effects
downstream of proteinuria (de Zeeuw, 2008). It is well recognized
that proteinuria (ultrafiltrated plasma proteins) activates tubular
cells to secrete many chemokines and mediators that can elicit
proinflammatory and profibrotic cascades (Eddy, 2004; Zoja
et al., 2004; Bakris, 2008; Moreno et al., 2014), and leads to renal
inflammation and fibrosis (Abbate et al., 2006). An additional
treatment option is thus to reduce tubulointerstitial changes
secondary to proteinuria.
We previously showed that proteinuria can promote renal
lymphangiogenesis that concomitantly occurs with an increase of
the profibrotic response and tubular activation (Yazdani et al., 2012).
Several studies have proposed both a direct and an indirect link
between lymphangiogenesis, inflammation and fibrotic reactions.
Nevertheless, their causal interplay in tubulointerstitial remodeling
in kidney diseases has not been investigated yet (Yazdani et al.,
2014). A wealth of evidence has shown a reciprocal interaction
between inflammation and lymphangiogenesis (Johnson and
Jackson, 2010; Dieterich et al., 2014). On one hand, leukocytes are
able to produce mediators and growth factors that can promote
lymphangiogenesis, and, on the other hand, activated lymph
endothelial cells (LECs) can secrete several mediators that recruit
inflammatory cells and can further exacerbate this inflammatory
microenvironment (Loffredo et al., 2014). Among inflammatory
cells, macrophages have been shown to play a prominent role in
inducing lymphangiogenesis, at least in two distinct ways: by
producing lymphangiogenic growth factors and stimuli, and/or
by directly trans-differentiating into LECs (Ran and Montgomery,
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The direct link between inflammation and fibrosis has been well
established as well (Wick et al., 2013). Despite many clinical and
experimental investigations, effective treatment for fibrosis is still
lacking in the clinic (Friedman et al., 2013). FTY720, an S1P
analog, effectively inhibits the egress of T and B cells from lymph
nodes (Kabashima et al., 2006; Matloubian et al., 2004), thereby
reducing the number of antigen-primed/restimulated cells that
recirculate to peripheral inflammatory tissues (Brinkmann and
Lynch, 2002), and consequently halts inflammation. FTY720 can
also directly block lymphangiogenesis (Yoon et al., 2008), and has
been reported to prohibit renal fibrogenesis (Shiohira et al., 2013; Ni
et al., 2013a,b). Taking these all into account, FTY720 seems to be a
promising agent in targeting tubulointerstitial remolding. However,
the exact interaction among these interstitial phenomena
(inflammation, fibrosis and lymphatic remodeling) in proteinuric
nephropathy has not been clearly explored. Understanding of the
detailed mechanisms of the complex interaction between these
proteinuria-induced downstream tubulointerstitial events might
reveal their significance to the progression towards ESRD, and
hence might have potential therapeutic values in affected
individuals.
To mimic a clinically relevant situation, a mild proteinuric model
was chosen: thus, a low amount of adriamycin was used to induce
moderate proteinuria, without the development of nephrotic
syndrome but with chronic tubular epithelial cell activation and
progressive interstitial remodeling. In this model, we chose a therapy
aimed at reducing interstitial remodeling, thus not aiming to reduce
proteinuria even further, but to target its downstream consequences.
Therefore, in this interventional studywe specifically blocked lymph
vessel (LV) formation (antibody treatment with anti-VEGFR3),
monocyte/macrophage influx (clodronate liposomes, which
selectively deplete monocytes/macrophages), and lymphocyte
and α-SMA-positive-cell influx (by oral FTY720, as an S1P
receptor agonist) separately to investigate the role of each of
these phenomena in tubulointerstitial remodeling in proteinuric
nephropathy. As read-out parameters we evaluated proteinuria and
histological changes.
RESULTS
Proteinuria developed over time in adriamycin-injected rats
Urinary protein excretion was significantly increased at week 6 in
the adriamycin-injected rats compared with their saline-injected
controls [146 (ranging from 77 to 230) in adriamycin-injected rats
vs 18 (13-27) mg/24 h in control rats; P<0.001]. Except for
proteinuria, at week 6 other clinical parameters, such as body
weight, blood pressure and kidney function, evidenced by creatinine
clearance, were not significantly different between healthy and
proteinuric rats, but heart rate was reduced in proteinuric rats
(Table 1). Also, there was no difference in water intake between
both groups of rats at that time. However, food intake was
significantly higher in the proteinuria rats (Table 1). In this way,
we developed a model of so-called pure proteinuria without signs of
nephrotic syndrome.
Histological inspection of the kidneys revealed that, at 6 weeks, a
non-significant influx of α-SMA-positive cells was observed in
adriamycin-injected rats compared with healthy controls.
Otherwise, no changes were seen in week-6 proteinuric kidneys,
neither for number of LVs, ED-1-positive macrophages and CD3-
positive T cells, nor for interstitial fibrosis evidenced by collagen III
quantification (Fig. 1) and periodic acid-Schiff (PAS) staining (not
shown at week 6). In contrast, at week 12, tubulointerstitial tissue
remodeling occurred. This was characterized by lymphangiogenesis
measured by an increase in LV density (Fig. 1C), increased numbers
of ED-1-positive macrophages (Fig. 1F) and CD3-positive T cells
(Fig. 1I), increased α-SMA-positive myofibroblasts (Fig. 1L), and
interstitial fibrosis measured by collagen III deposition (Fig. 1O)
and PAS staining (Fig. 2K).
Anti-VEGFR3 antibody totally prevented LV formation in
proteinuric rats
Treatment for 6 consecutive weeks with anti-VEGFR3 antibody
(IMC-3C5) in proteinuric rats (weeks 6-12) did not significantly
alter proteinuria, compared with non-treated proteinuric controls.
No noticeable changes were observed in body weight, blood
pressure, heart rate, food and fluid intake, and creatinine
clearance compared with untreated proteinuric rats (Table 1). On
histology, proteinuric kidneys at week 12 presented significantly
more podoplanin-positive LVs by immunohistochemistry in the
cortical interstitium, compared to week 6, implying renal
lymphangiogenesis between weeks 6 to 12 (Fig. 1A-C; P<0.05).
TRANSLATIONAL IMPACT
Clinical issue
Proteinuria (high levels of proteins in the urine) is a major challenge in
clinical nephrology. Sustained proteinuria might lead to progressive loss
of renal function, which will eventually require dialysis or renal
transplantation. Routine anti-proteinuric treatment regimens are not
always completely successful, and residual proteinuria might also cause
irreversible tissue damage and, ultimately, loss of kidney function. This
underlines the urgent need for other therapeutic strategies, not aimed at
eliminating residual proteinuria but at preventing proteinuria-induced
renal injury, instead. Hence, strategies targeting the downstream effects
of proteinuria to preserve kidney function are highly desirable.
Results
In this study, the authors used adriamycin-injected rats, a well-
established model in which the animals develop proteinuria 6 weeks
post-injection. At this stage, lasting for other 6 consecutive weeks, anti-
proteinuric treatments started, which targeted specifically three major
proteinuria-associated tubulointerstitial changes: lymphangiogenesis
(via anti-VEGFR3 antibody), monocyte/macrophage influx (via
clodronate liposomes) and interstitial fibrosis (via the S1P agonist
FTY720). At week 12, proteinuric rats showed a significant increase of
renal lymphangiogenesis, inflammatory cell influx (as evidenced by
increased macrophage and T-cell numbers) and fibrosis markers [as
evidenced by myofibroblasts accumulation, collagen III deposition and
periodic acid-Schiff (PAS) scoring, a measure of interstitial fibrosis]. Anti-
VEGFR3 antibody completely inhibited lymphangiogenesis in
proteinuric rats; however, it had no significant effect on inflammatory
cells, fibrotic markers or proteinuria. Clodronate liposomes reduced
macrophage influx and partly prevented myofibroblast increase but
showed no effects on renal lymphangiogenesis, fibrotic markers or
proteinuria. FTY720 markedly reduced myofibroblast accumulation,
T-cell infiltration and interstitial fibrosis (not collagen III deposition), and
partially reduced macrophage number and proteinuria, but had no
influence on lymphangiogenesis.
Implications and future directions
These results suggest that targeting any of the downstream
tubulointerstitial changes of protenuria individually is not an effective
strategy, at least under proteinuric conditions. Future treatments should
aim for combination therapies. Alternatively, because activated tubular
epithelial cells are known to mediate tubulointerstitial-tissue remodeling,
future strategies could be developed to test whether preventing the
activation of tubular epithelial cells in proteinuric conditions or blocking
and/or inactivating the chemokines and mediators that these cells
secrete can reduce proteinuria-induced renal injury.
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IMC-3C5 treatment showed a robust and significant decrease in the
amount of LVs, not only in the proteinuric rat kidneys, compared
with non-treated proteinuric rats (P<0.001), but also in the kidneys
of healthy rats upon treatment, compared with the non-treated
healthy controls (Fig. 2A,B; P<0.001). Looking at macrophages
and T cells, although the proteinuric rats treated with IMC-3C5
showed a trend in reducing the ED1-positive macrophages, this was
not statistically significant (Fig. 2C,D). Rats treated with IMC-3C5
antibody did not show any marked changes in T-cell number
(Fig. 2E,F). α-SMA and collagen III expression and interstitial
fibrosis (scored by PAS staining) did not show any marked changes
after IMC-3C5 treatment (Fig. 2G-L). Regarding mRNA level
[quantitative reverse transcriptase polymerase chain reaction
(qRT-PCR)], IMC-3C5 treatment decreased the collagen III (α1)
mRNA level almost significantly, but not collagen I (α1) and
TGF-β1. This intervention did not show significant effects on
inflammatory marker vascular cell adhesion molecule 1 (VCAM-1),
monocyte chemoattractant protein-1 (MCP-1/CCL2) and
osteopontin (Fig. 3), although a tendency towards a reduction of
these inflammatory markers was suggestive. There were no
significant differences for total white blood count, lymphocytes,
neutrophils, basophils and eosinophils in IMC-3C5-treated
groups. Thus, treatment of proteinuric rats with anti-VEGFR3
completely prevented tubulointerstitial LV formation, however
without prominent changes in tubulointerstitial inflammatory and
fibrotic markers.
FTY720 prevented the increase in myofibroblast
accumulation, T-cell infiltration and interstitial fibrosis, but
not collagen III deposition, macrophage influx or LV number
Treatment of proteinuric rats with FTY720 did not affect body
weight, food and water intake, blood pressure, heart rate, creatinine
clearance or proteinuria (Table 1). FTY720 treatment had no effect
on renal lymphangiogenesis (Fig. 4A,B). The influx of ED1-positive
macrophages showed a tendency to be reduced upon FTY720
treatment, although not significantly (Fig. 4C,D). Because the
number ofwhite blood cells and leukocyteswere strongly reduced by
FTY720 treatment (Fig. 8A,B; P<0.001), renal influx of CD3-
positive T cells was significantly reduced at 12 weeks (Fig. 4E,F;
P<0.05). FTY720 completely prevented α-SMA-positive
myofibroblast accumulation at week 12 compared with non-treated
proteinuric rats (Fig. 4G,H; P<0.05), but did not show any marked
effect on collagen III deposition by immunohistochemistry (Fig. 4I,J).
Nevertheless, this intervention significantly reduced interstitial
fibrosis scored by PAS staining (Fig. 4K,L; P<0.05). At the
mRNA level, FTY720 also could not prevent the increase in collagen
I (α1), collagen III (α1), TGF-β1, MCP-1/CCL2 and osteopontin,
although significantly prevented the increase of VCAM-1 mRNA
expression (Fig. 5). In summary, in the kidneys of FTY720-treated
proteinuric rats, accumulation of α-SMA-positive myofibroblasts,
CD3-positive T cells and interstitial fibrosis were prevented;
however, there was no effect on collagen III deposition,
macrophage influx and lymphangiogenesis.
Clodronate liposome prevented macrophage influx in the
kidney without any major effect on other histological and
clinical parameters
Targetingmonocyte/macrophages by clodronate liposomes (CLs) in
proteinuric rats did not result in changes in body weight, blood
pressure, heart rate, food and water intake, creatinine clearance and
proteinuria (Table 1). This treatment also did not prevent the
formation of new LVs in proteinuric rats compared with non-treated
proteinuric control rats (Fig. 6A,B). However, kidneys of proteinuric
rats showed a significant decrease in macrophage number upon CL
treatment (Fig. 6C,D; P<0.05), whereas proteinuric rats treated by
‘placebo’ liposomes (PBS instead of clodronate) showed a small
non-significant reduction (Fig. 6D). Even in non-proteinuric healthy
controls treated with CLs, the number of kidney macrophages
significantly decreased compared with non-treated healthy controls
(Fig. 6D; P<0.01). CL treatment did not influence the number of
circulating white blood cells and lymphocytes in the blood (Fig. 8).
Treatment of proteinuric rats with CLs, despite effective prevention
of macrophage influx, did not significantly influence influx of T
cells, myofibroblast accumulation, interstitial fibrosis or collagen III
deposition (Fig. 6E-L). At the mRNA level, this treatment also did
not show any marked effect on collagen I (α1), collagen III (α1),
TGF-β1 and osteopontin, whereas it inhibited the increase in mRNA
expression of MCP-1/CCL2 and VCAM-1 (Fig. 7). Thus, despite
effective reduction of renal inflammation by CL treatment,
interstitial fibrosis and lymphangiogenesis was not influenced by
this intervention.
DISCUSSION
In the adriamycin-induced proteinuria model, we targeted
tubulointerstitial lymphangiogenesis (VEGFR3 blockade),
monocyte/macrophage influx (depletion by CLs), and pre-fibrotic
Table 1. General parameters at 12 weeks
General parameters Healthy (n=6) Proteinuric rats (n=8) 3C5 (n=8) FTY720 (n=8) CL (n=8)
General
Weight (g) 487.0 (441.3-492.3) 447.5 (424.0-453.5) 428.5 (408.3-449.5) 437.0 (419.5-455.3) 433.5 (389.3-465.0)
Blood pressure (mm/Hg)
Systolic 144.0 (121.0-149.0) 136.5 (119.0-143.5) 129.5 (120.5-155.0) 141.5 (123.8-149.8) 126.0 (120.0-161.8)
Diastolic 87.0 (67.0-97.5) 88.5 (79.3 (98.0) 78.0 (69.3-102.8) 87.5 (80.5-98.8) 83.5 (74.8-108.0)
Mean 108.0 (85.0-116.0) 106.0 (95.3-114.5) 95.5 (88.0-121.3) 108.0 (97.3-113.8) 100.5 (92.3-126.8)
Heart rate (bpm) 409.0 (400.0-414.0) 377.5 (337.8-380.0) (P=0.031) 321.0 (302.5-388.3) 354.0 (344.5-390.8) 371.0 (329.5-409.8)
Fluid intake (g/24 h) 24.1 (12.7-28.3) 23.9 (18.3-33.0) 25.6 (15.9-30.3) 20.9 (15.2-23.5) 22.6 (16.1-32.9)
Food intake (g/24 h) 11.7 (10.6-13.7) 16.6 (13.3-19.6) (P=0.022) 16.6 (10.0-20.7) 14.3 (11.9-18.0) 17.4 (15.5-21.9)
Kidney function
Creatinine clearance (ml/min) 4.9 (4.4-5.2) 4.5 (4.2-5.1) 5.4 (5.0-5.8) 4.2 (3.8-4.6) 4.9 (4.2-5.7)
Total protein (g/l) 26.4 (22.6-60.6) 337.6 (175.7-535.1) (P=0.002) 300.0 (204.1-554.2) 240.2 (94.3-334.5) 223.4 (166.0-522.3)
Groups are divided into healthy untreated rats, proteinuric untreated rats, and proteinuric rats treated with anti-VEGFR3 antibody (3C5), FTY720 or clodronate
liposomes (CL). The table shows that, in the proteinuric rats, urinary protein excretion increased compared to the healthy controls. The proteinuric rats treated with
3C5, FTY720 and CL did not show any significant differences compared to untreated proteinuric rats.
The table shows medians and interquartile ranges. All P-values below <0.05 are shown (bold) (only significant for proteinuric rats compared with healthy
controls).
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myofibroblast accumulation and interstitial fibrosis (by the S1P
agonist FTY720). Anti-VEGFR3 antibody completely blocked
renal lymphangiogenesis in proteinuric rats. Nevertheless, on a
histological level, the anti-VEGFR3 antibody did not show any
major effects on inflammatory (macrophages and T cells) or fibrotic
(α-SMA, collagen III and interstitial fibrosis) markers despite some
apparent reductions in fibrotic and inflammatory markers at the
mRNA level. FTY720 considerably prevented α-SMA-positive
myofibroblast accumulation and interstitial fibrosis, but not
collagen III deposition and lymphangiogenesis. The treatment of
Fig. 1. Development of renal lymphangiogenesis, inflammation and fibrosis in an adriamycin-induced proteinuria model. Representative
photomicrographs show the differences in several markers in the kidneys of healthy rats, and in proteinuric rats at week 6 and week 12. (A-C) Podoplanin+ LVs
(arrows); (D-F) ED1+ macrophages (arrows); (G-I) CD3+ T cells (arrows); (J-L) α-SMA+ myofibroblasts; (M-O) collagen III deposition. All markers were
significantly increased at week 12 in proteinuric rats compared with the healthy controls at week 12 and the proteinuric rats at week 6. For quantification of these
data at 12 weeks between proteinuric rats with and without treatment, see Figs 2, 4 and 6. Magnification: (A-C;J-O) 200×; (D-I) 400×.
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proteinuric rats with CL prevented the increase in tissue macrophage
number in proteinuric kidneys, but did not show major changes on
the clinical parameters, neither on tubulointerstitial
lymphangiogenesis nor fibrotic markers. This study thereby
shows the dissociation of inflammatory (macrophages, T cells) or
fibrotic (myofibroblasts, collagen III and interstitial fibrosis)
responses from renal lymphangiogenesis, at least in this
proteinuric-nephropathy model. Importantly, proteinuria-induced
Fig. 2. Effectsof anti-VEGFR3antibody treatmenton renal lymphangiogenesis, inflammation and fibrosis.Quantification of renal cortical podoplanin-positive
vessel-like structures of the ratswho received treatmentwith anti-VEGFR3antibody (IMC-3C5) showedasignificant reduction of LVnumberat 12 weeks (A,B; 400×),
whereas it showedanon-significant trend in reducing thenumberofmacrophages in thecortical interstitiumof proteinuric rats (C,D; 400×), anddidnot influenceT-cell
influx (E,F; 400×) at week 12. Anti-VEGFR3 antibody also did not have a significant effect on α-SMA (G,H; 200×), collagen III deposition (I,J; 200×) and interstitial
fibrosis (K,L; 200×). White dotted bars represent week 6 before treatment; black bars represent week 12 after treatment. The PAS staining quantification
(interstitial fibrosis) is showed at 12 weeks. HL, healthy; PR, proteinuric untreated; 3C5, anti-VEGFR3 antibody. *P<0.05, **P<0.01, ***P<0.001.
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interstitial fibrosis cannot be halted by blocking lymphangiogenesis
or the influx of macrophages.
Tubulointerstitial remodeling is one of the key events in
proteinuric nephropathy, which in the end causes massive renal
fibrosis culminating into loss of renal function and ESRD
(Nangaku, 2004; Theilig, 2010). Although targeting proteinuria
directly is the most commonly used and effective treatment in the
clinic, complete annihilation of proteinuria is very difficult and
attempts to do so resulted in increased mortality (Nangaku, 2004;
Khan et al., 2013; Hou et al., 2007; Chen et al., 2014). Therefore,
preventing and/or curing damage downstream of proteinuria in the
kidney would be of high importance in order to preserve kidney
function, and halt progression towards CKD and eventually ESRD.
Vascular remodeling plays a major role in tubulointerstitial
homeostasis in the microenvironment of all organs, and specifically
in the kidney (Rienstra et al., 2010; Schrijvers et al., 2004).
Lymphangiogenesis, the growth and formation of new LVs, has
caught increasing attention over the last years owing to its immense
importance in many pathological conditions in the body (Alitalo,
2011). Lymphangiogenesis has been shown to be in close relation
to fibrogenesis in different organs, including the kidney (Sakamoto
et al., 2009; Zampell et al., 2012; El-Chemaly et al., 2009). Yet, the
causal interplay between fibrosis and lymphangiogenesis has not
been clearly explored. Meinecke et al. showed in an elegant study
that LVs play a central role in fibrogenesis, at least in pulmonary
fibrosis (Meinecke et al., 2012). They meticulously showed that,
in the early stage of the disease, activated LECs stimulate PDGFR-
β-expressing mural cells by secretion of platelet derived growth
factor-B (PDGF-B), recruiting these cells around LVs and then by
attaching to LVs, impeding their drainage capacity. These defects
then hamper the most important function of LVs, which is fluid
drainage, and thereby lead to fibrotic processes in the lung.
Although it is not yet known whether this phenomenon holds true
in renal fibrosis, this study proposed an important role of LVs in
fibrogenesis. CCL21, by signaling CCR7-receptor-expressing cells,
initiates a vital pathway in renal fibrogenesis (Sakai et al., 2006).
LECs of renal LVs are also able to secrete CCL21 (Kerjaschki
et al., 2004). Because blocking of lymphangiogenesis by anti-
VEGFR3 decreases CCL21 secretion (Nykänen et al., 2010), this
strategy might be useful in targeting fibrosis. We previously showed
that, in the experimental unilateral proteinuric model, prolonged
and sustained proteinuria triggers new LV formation in the kidney
and that renal lymphangiogenesis occurs before the influx of
macrophages and collagen deposition (Yazdani et al., 2012).
To explore the importance of LVs in tubulointerstitial damage
and its potential roles in modulating the microenvironmental
milieu, we targeted lymphangiogenesis specifically. Anti-VEGFR3
antibodies have been extensively studied in experimental models,
and are currently in Phase 1 clinical trial for the treatment
of advanced malignant tumors (http://clinicaltrials.gov/ct2/show/
NCT01288989). Therefore, in this current study, by specific
blocking of lymphangiogenesis in a renal injury model, we aimed
to explore more about its involvement in this disease. In this study,
IMC-3C5 completely blocked lymphangiogenesis in our
proteinuric model in rats and also in the healthy controls, which
indicates LV regression (Mäkinen et al., 2001). This intriguing
observation needs further studies to see what could be the
consequence of this decrease in LV number, such as edema
formation or delaying exit of inflammatory cells, etc. This
intervention, however, failed in preventing renal inflammation (at
least not macrophage and T-cell number) and fibrosis (at least not
α-SMA and collagen III expression, and interstitial fibrosis scored
by PAS staining), although some apparent effects on mediators of
inflammation and fibrosis on mRNA level is suggested by qRT-
PCR data. The reason might be that, in this model, tubular epithelial
cells, which continuously encounter the ultrafiltrated plasma
proteins and are being activated, are the main source of many
chemokines and mediators that induce tubulointerstitial remolding
such as lymphangiogenesis, inflammation and fibrosis (Moreno
et al., 2014).
LVs are an integral part of the inflammatory process, and they
have been proposed as a therapeutic target in inflammation (Johnson
Fig. 3. Effects of anti-VEGFR3 antibody treatment on mRNA expression of fibrotic and inflammatory markers. Anti-VEGFR3 injections tended to reduce
the proteinuria-induced expression of collagen III (α1) and TGF-β1 mRNA, but not collagen I (α1) (A-C). Likewise, anti VEGFR3 intervention tended to reduce
the proteinuria-induced mRNA expression of MCP-1, osteopontin and VCAM-1 (D-F). HL, healthy; PR, proteinuric untreated; 3C5, anti-VEGFR3 antibody.
*P<0.05, **P<0.01, ***P<0.001.
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and Jackson, 2010; Dieterich et al., 2014; Kim et al., 2012).
Different leukocytes are capable of prompting lymphangiogenesis
(Loffredo et al., 2014); however, among them, the role of
macrophages is far more highlighted (Ran and Montgomery,
2012; Kerjaschki, 2005), and macrophage depletion or reduction
has been shown to abolish lymphangiogenesis in several disease
Fig. 4. Effects of FTY720 treatment on renal lymphangiogenesis, inflammation and fibrosis. Quantification of the staining of kidneys from proteinuric rats
treated with FTY720 did not showany effect on the increased number of LVs in proteinuric rats at week 12 (A,B). Although FTY720 did not showa significant effect
on the influx of macrophages (C,D), it did show a complete blocking of T-cell influx at week 12 compared with the untreated proteinuric rats (E,F) and also of
α-SMA-positive cells at 12 weeks (G,H), whereas it did not show a significant effect on collagen III deposition (I,J). Nevertheless, interstitial fibrosis (PAS scoring)
revealed that FTY720 could markedly prevent the development of interstitial fibrosis in proteinuric rats compared with healthy controls at week 12 (K,L). White
dotted bars represent week 6 before treatment; black bars represent week 12 after treatment. PAS staining and quantification has been done at week 12.
HL, healthy; PR, proteinuric untreated; FTY, FTY720. *P<0.05, **P<0.01, ***P<0.001.
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models (Poosti et al., 2012; Maruyama et al., 2012). Still, the role of
macrophages, specifically in renal lymphangiogenesis, is not
distinguished clearly. Several groups, including ours, have shown
thatmacrophages are actively involved in inducing lymphangiogenesis
in kidney diseases (Yazdani et al., 2014); however, there are some
conflicting findings in these studies. Lee et al. (2013) depleted
macrophages by CLs in unilateral ureteral obstruction (UUO)
kidney damage in mice and found the striking blockage of
lymphangiogenesis. In a rat UUO model, Suzuki et al. (2012)
showed tubular epithelial cells to be the main inducer of renal
lymphangiogenesis. It seems that, at least in this experimental
model, macrophages are not the main lymphangiogenic inducer. We
now showed that complete prevention of tubulointerstitial
macrophage influx also reduced some markers of inflammation at
the mRNA level. However, neither interstitial fibrosis nor
lymphangiogenesis could be reduced by this intervention. Hence,
the role of macrophages in inducing lymphangiogenesis seems to be
very much context-dependent.
FTY720, an FDA-approved drug to treat multiple sclerosis,
exerts different kinds of effects in the body (Halmer et al., 2014;
Pitman et al., 2012). One of the most well-known influences is the
immunosuppression by blocking the egress of lymphocytes from the
lymph nodes, thereby reducing inflammation (Kabashima et al., 2006;
Matloubian et al., 2004). Several reports have shown the beneficial
effect of FTY720not only in a renal inflammatory reactions, but also in
hampering renal profibrotic and fibrotic development, e.g.
myofibroblast activation and collagen deposition (Shiohira et al.,
2013; Ni et al., 2013a,b). By binding to the S1P1 receptor on LECs,
FTY720proved to bean effective drug in blocking lymphangiogenesis
(Yin et al., 2011). In this current study, FTY720 treatment effectively
reduced the number of lymphocytes in the blood circulation, and T
cells in proteinuric kidneys, but did not have any impact on renal
lymphangiogenesis. Interestingly, although FTY720 significantly
prevented the increase of α-SMA-positive myofibroblasts, it was not
effective in decreasing collagen III deposition, although it significantly
reduced tubulointerstitial fibrosis (PAS scoring). Apparently, collagen
III is not fully representative for interstitial fibrosis,which is a reflection
of interstitial matrix accumulation of many different extracellular
matrix molecules. Results also showed that α-SMA is not an ideal
marker for collagen-secreting cells in interstitial injuries, because
many (myo)fibroblasts that do not express α-SMA are able to deposit
collagen (Boor et al., 2010; Farris andColvin, 2012;Hinz et al., 2012).
In summary, our study showed that tubulointerstitial fibrosis,
inflammation and lymphangiogenesis are rather independent tissue
remodeling responses, at least under proteinuric conditions. Our
work also shows that blocking renal interstitial lymphangiogenesis
or inflammation did not effectively reduce the development of renal
fibrosis. It proposes that, for the treatment of the downstream
consequences of proteinuria, there is no specific target in just one of
the tubulointerstitial changes that we investigated in this study. Data
rather suggest a combination of intervention strategies to reduce
proteinuria-driven tubulointerstitial tissue remodeling is required,
e.g. by combining FTY720 or CLs with lymphangiostatic treatments
to evaluate the effects on fibrosis and functional renal outcome
parameters. Earlier data indicated that activated tubular epithelial
cells trigger lymphangiogenesis, inflammation and fibrosis. Our
group previously showed that specific targeting of the Rho-kinase
pathway in proximal tubular epithelial cells markedly reduced renal
inflammation and renal lymphangiogenesis in an acute renal
allograft rejection model (Poosti et al., 2012). Although it
warrants future studies, these findings suggest that strategies to
preserve tubular epithelial cells or directly target their secreted
chemokines and mediators could be a promising approach in
preventing or treating tubulointerstitial damages secondary to
proteinuria.
MATERIALS AND METHODS
Animal experimental protocol and treatments
Proteinuria was induced in 78 3-month-old male Wistar rats (weighing 180-
200 g) by single injection of adriamycin in the tail vein [1.8 mg/kg body
weight (BW)], and healthy rats served as controls. After 6 weeks, when
proteinuria had developed (∼150 mg/24 h), a kidney biopsy was taken via
dorsolateral incision. After recovery, 60 rats were assigned randomly to one
of the interventional or control groups. 18 rats did not develop sufficient
proteinuria and were excluded from the study. Proteinuric rats were
Fig. 5. Effects of FTY720 treatment on mRNA expression of fibrotic and inflammatory markers. Quantitative RT-PCR data showed that the mRNA
expression of fibrotic and inflammatory markers, which have been increased significantly upon proteinuria (A-F), was not reduced by FTY720 treatment (A-E),
except for significant prevention of VCAM-1 mRNA increase (F). HL, healthy; PR, proteinuric untreated; FTY, FTY720. *P<0.05, **P<0.01, ***P<0.001.
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randomly divided into five groups: a proteinuric untreated group (n=8), and
four interventional groups, which were treated with FTY720 (n=8), anti-
VEGFR3 antibody (n=8), CLs (n=8) or empty (PBS) liposomes (n=6),
which served as a control for the CLs. The healthy rats were randomly
divided into a healthy untreated control group (n=6) and three different
healthy control groups, which were treated with FTY720 (n=6), anti-
VEGFR3 antibody (n=4) or CLs (n=6). The treatment by the above-
mentioned agents then started from week 6 and was continued until
Fig. 6. Effects ofmacrophages depletion byCLs on renal lymphangiogenesis, inflammation and fibrosis.Quantification of immunohistochemical stainings
of the kidneys of CL-treated proteinuric rats did not prevent the increase in LV number in proteinuric rats (A,B) despite completely blocking macrophage influx
at week 12 (C,D). However, this treatment had no obvious effect on T-cell influx (E,F), and did not have a significant effect on α-SMA (G,H) or collagen III
deposition (I,J). In the same line, the development of interstitial fibrosis was also not inhibited by CL intervention (K,L). White dotted bars represent week 6 before
treatment; black bars represent week 12 after treatment. The PAS staining quantification (interstitial fibrosis) is shown at 12 weeks. HL, healthy; PR, proteinuric
untreated; CL, clodronate liposome; EL, empty liposomes. *P<0.05, **P<0.01, ***P<0.001.
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week 12: anti-VEGFR3 antibody (IMC-3C5, ImClone/Eli Lilly, USA)
intraperitoneally (i.p.) 40 mg/kg BW, three times per week; CLs
(ClodronateLiposomes.org, The Netherlands) i.p. twice weekly 1 ml/rat;
and FTY720 (Novartis, Basel, Switzerland) 1 mg/kg BW/day in drinking
water. At week 12, blood pressure was measured under general anesthesia
with the Cardiocap/5 (Datex-Ohmeda, Newark, USA). Then, after saline
perfusion, organs were harvested and some parts were preserved in liquid
nitrogen for cryosections, and other parts in formaldehyde 10% for paraffin
embedment.
At the beginning of the study, at the time of the biopsy (6 weeks) and at the
end of the experiment (12 weeks), body weight was measured, blood samples
were collected and rats were placed in metabolic cages for 24 h for urine
collection and the measurement of food and water intake. Proteinuria was
determined in urine samples by a turbidimetric assay (Roche Modular P,
Mannheim,Germany). Experimental procedureswere carried out according to
the national guidelines for the care anduse of laboratoryanimals, and approved
by the local Animal Ethics Committee of the University of Groningen.
Immunohistochemistry
Staining was performed on 3-μm-thick formalin-fixed paraffin sections after
deparaffinization in xylene and rehydration in alcohol series. Antigen
retrieval was done for 15 min in a microwave oven for Tris/EDTA buffer
pH:9 and citrate buffer pH:6, or overnight at 80°C in Tris/HCl buffer pH:8.
Endogenous peroxidase activity was blocked with 0.3% hydrogen peroxide.
Sections were incubated for 1 h or overnight at 4°C with the following
primary antibodies: mouse anti-human α-SMA (clone 1A4, Sigma-Aldrich,
St Louis, USA), goat anti-collagen III (cat. no. 1330-01, SouthernBiotech,
Birmingham, USA), rabbit anti-rat CD3 (clone A0452, Dako, Glostrup,
Denmark), mouse anti-rat CD68 (clone ED1, AbD Serotec, Oxford, UK)
and mouse anti-rat podoplanin (cat. no. 11-035, Angio Bio, Del Mar, USA).
After this step, the sections were incubated with secondary and tertiary
antibodies diluted in PBS/BSA 1% and 1% normal rat serum. We used
rabbit anti-mouse Ig horseradish peroxidase (HRP), goat anti-rabbit Ig HRP,
goat anti-mouse Ig HRP, rabbit anti-goat Ig HRP, swine anti-rabbit HRP and
anti-rabbit poly HRP (all from Dako, Glostrup, Denmark). As negative
Fig. 7. Effects of CL treatment onmRNA expression of fibrotic and inflammatorymarkers. Targeting macrophages by CLs did not markedly alter the mRNA
expression of the fibrotic markers collagen I (α1), collagen III (α1) and TGF-β1 compared with non-treated proteinuric rats (A-C). The CL intervention strongly
prevented the increase of VCAM-1 mRNA expression in proteinuric rats (F). MCP-1 expression was non-significantly (P<0.06) reduced by CL treatment (E),
whereas osteopontin expression was not influenced by the treatment (D). HL, healthy; PR, proteinuric untreated; CL, clodronate liposome; EL, empty liposome.
*P<0.05, **P<0.01, ***P<0.001.
Fig. 8. Number of total white blood cells (WBCs) and lymphocytes in the blood in both healthy and proteinuric rats at week 12. Total WBCs did not show
any difference in healthy non-proteinuric compared to proteinuric rats (A). However, upon treatment with FTY720, the total WBCs dramatically decreased at week
12, in both healthy (white dotted bars) and proteinuric (black bars) groups. CL and IMC-3C5 did not show any effect. In order to see the effect of treatments on
specific subsets of WBCs in the blood, we also measured the number of lymphocytes. FTY720 markedly reduced the number of lymphocyte in the circulation,
even in healthy rats who received the drug. However, again the other two interventions did not have any effect on lymphocyte number in the blood circulation
(B). HL, healthy; PR, proteinuric untreated; CL, clodronate liposome; EL, empty liposome; 3C5, anti-VEGFR3 antibody; FTY, FTY720. *P<0.05, **P<0.01,
***P<0.001.
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controls, the primary antibodies were replaced by PBS/BSA 1%. Bound
antibodies were visualized by aminoethylcarbazole (AEC) or by the
peroxidase substrate 3,3′-diaminobenzidine (DAB) (Sigma-Aldrich,
St Louis, USA) and then counterstained with diluted hematoxylin. PAS
was also performed on series of sections in order to quantify the extent of
structural changes (interstitial fibrosis). The sections were then scanned by a
NanoZoomer HT (Hamamatsu Photonics K.K., Shizuoka Pref., Japan). The
quantification was done using Aperio ImageScope software (version
9.1.772.1570, Aperio Technologies Inc., Vista, CA, USA) and ImageJ
1.46r (Rasband, W.S., U.S. National Institutes of Health).
Quantification of LVs and renal histomorphology
For identification of LVs, we counted podoplanin-positive vessels in 30
cortical interstitial fields per kidney. The amount of collagen III,
myofibroblasts (α-SMA), ED1-positive macrophages and CD3-positive T
cells were measured as described previously (Yazdani et al., 2012). In short,
collagen III expression, myofibroblasts, ED1-positive macrophages and
CD3-positive T cells were evaluated in 30 (high or medium power field)
cortical interstitial areas of each kidney in a blinded fashion. The
quantification was done using ImageJ 1.41 (Rasband, W.S., U.S. National
Institutes of Health). PAS staining was semi-quantitatively scored on a scale
ranging from 1 to 5. The scoring indicates which part of renal cortical tissue
was affected by tubulointerstitial fibrosis (broadening interstitial area in
between the tubules): score 1: <1%; score 2: 1-5%; score 3: 6-10%; score 4:
11-20%; score 5: 21-50%.
Urine and plasma analysis
The sodium, potassium and chloride concentrations in both plasma and
urine were analyzed by an electrolyte analyzer ISE (Roche Modular P,
Mannheim, Germany). The urea and creatinine in plasma and urine were
measured by an enzymatic UV assay (Roche Modular P). For the
measurement of total protein in plasma/serum, we used a colorimetric
assay (Roche Modular P).
RNA isolation and cDNA synthesis
For RNA isolation from kidney tissue, we used the Favorprep RNA minikit
(Favorgen Biotech Corp., Denmark). For each sample, we used 5-µm
sections, in total weighing approximately 30 mg (no DNase treatment
during RNA isolation). Concentration measurement was done by Nanodrop
and the integrity of the RNA was tested by running the samples on a 1%
agarose gel in loading buffer. cDNA was synthesized using a QuantiTect
Reverse Transcription Kit (Qiagen, Germany). Genomic DNA was
eliminated during this procedure.
RT-PCR
mRNA expression of osteopontin, MCP-1 (CCL2), VCAM-1, collagen I
(α1), collagen III (α1) and TGF-β1 were determined by qRT-PCR. Primers
were bought fromQIAGEN, The Netherlands. Primers were: collagen I (α1)
primer (5′-AGCCTGAGCCAGCAGATTGA-3′ and 5′-CCAGGTTGCA-
GCCTTGGTTA-3′), MCP-1 primer (5′-CCGACTCATTGGGATCAT-
CTT-3′ and 5′-TGTCTCAGCCAGATGCAGTTAAT-3′). Other primers
were ordered ‘on demand’ with the following order names: Rn_Col3-
a1_2_SG QuantiTect primer assay (QT01083537), Rn_Tgfb1_1_SG
QuantiTect primer assay (QT00187796), Rn-Vcam1-1-SG QuantiTect
primer assay (QT00178500) and Rat-Spp-1 RT2 qPCR Primer assay
(osteopontin) (PPR44222B).
qRT-PCR was performed using the C1000 CFX384 from Bio-Rad, using
SYBR Green (SensiMix SYBR No-ROX kit, GC biotech). GAPDH was
used as a housekeeping gene to normalize mRNA expression. GAPDH
primers: (5′-CATCAAGAAGGTGGTGAAGC-3′ and 5′-ACCACCCTG-
TTGCTGTAG-3′). 6.7 ng cDNA per well were brought on a 384-well plate
(plateHard-Shell PCR plates, 384-well white well/CRL shell). Every
sample was measured in triplicate. The cycle procedure was as followed:
10 min at 95°C, with 40 repeats of a 15 s denaturation step at 95°C and a 15 s
extension and annealing step at 60°C, followed with a 5 s extension step at
72°C. A dissociation stage was added to ensure that the desired
amplification was detected. Results are expressed as 2-deltaCT, and
finally presented as relative expression to GAPDH.
White blood cell counting
The number of white blood cells, neutrophils, lymphocytes, monocytes,
eosinophils and basophils were measured by the Sysmex XN9000 (Kobe
Japan).
Statistical analysis
Statistical analyses were performed using SPSS 20.0 (SPSS Inc., Chicago,
IL, USA), and GraphPad Prism 5.0 (GraphPad Software Inc., La Jolla, CA,
USA) was used for making graphs and figures. Statistical differences were
tested using Mann–Whitney U-test. Because the PAS staining was scored
semi-quantitatively into five categories, by Chi-square analyses we
compared the number of kidneys without interstitial fibrosis (score 1)
with those showing interstitial fibrosis (score >1). P<0.05 was considered
statistically significant.
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